Invests in categories: BioTechDevelopmentMedtechDrugPlatformProductHealthTechResearchTechnologyDiagnostics
News
297
Portfolio
73
Mentions
101
Employees: 11-50
Investment Stage: Seed; Series A; Series B; Series C; Series D
Portfolio 73
Show more
News 297
| Date | Title | Description |
| 23.04.2024 | 10th LSX World Congress | General Partner Dirk Kersten will be participating in Day One of the event on the panel "Charti... |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman t... | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large anim... | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotec... |
| 22.04.2024 | Swiss Biotech Day 2024 | The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeuti... | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pi... |
| 17.04.2024 | Anglonordic Life Science Conference | Join Forbion Analysts Anne Marije van Harten, PhD and Alice Vickers, PhD, as they join over 350 dele... |
| 16.04.2024 | 0100 Conference Europe 2024 | Forbion's Head of Impact and ESG, Silva Dezelan, PhD will be a speaker at the 0100 Conference Europe... |
| 12.04.2024 | Prilenia to Present Latest Research from its Pridopidine Pro... | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical s... |
| 03.04.2024 | Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Off... | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical s... |
| 20.03.2024 | Forbion Invests in Capstan Therapeutics with participation i... | • Nanna Luneborg, PhD, MBA, General Partner at Forbion to join Capstan Board of Directors • Capstan ... |
| 19.03.2024 | Forbion co-leads oversubscribed $157M Series B Financing Rou... | • Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental ... |
| 18.03.2024 | Bio-Europe Spring 2024 | Bio-Europe Spring 2024 will take place from 18-20 March, 2024 in Barcelona, Spain. The event connect... |
| 12.03.2024 | Azafaros announces completion of 12-week Phase 2 RAINBOW stu... | Major milestone reached in bringing new treatment options to patients and their families Leiden, The... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application... | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical ... |
| 12.03.2024 | NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Cl... | -- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adj... |
| 29.02.2024 | Forbion co-leads €26 million Seed Financing with launch of O... | • The financing, led by Forbion and Novo Holdings, will support Orbis’ expansion and advancement of ... |
| 28.02.2024 | 17TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM FOR PARTNERING... | The 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 28th - 29th Fe... |
| 27.02.2024 | Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFE... | --Company Receives Five-year Exclusivity Extension Through GAIN Act -- SAINT-LOUIS, France & WEI... |
| 21.02.2024 | NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben ... | • Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD • The study w... |
| 20.02.2024 | Mestag Therapeutics Enlists Leading Cancer Biology and Immun... | Cambridge, UK, February 20, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new ... |
| 14.02.2024 | enGene Announces Oversubscribed $200 Million Private Placeme... | BOSTON and MONTREAL, Feb. 14, 2024 /CNW/ – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Co... |
| 13.02.2024 | NewAmsterdam Pharma Announces Pricing of $175.3 Million Publ... | NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.... |
| 01.02.2024 | Bio-Neuroscience | Bio-Neuroscience is the partnering and investment summit for global leaders in CNS neuroscience drug... |
| 30.01.2024 | Enterprise Therapeutics Closes £26 million ($33.1 million) S... | • Round led by new investor Panakes, with participation from all existing investors • Funding will s... |
| 29.01.2024 | ARMGO Pharma Publishes Positive Phase 1b Trial Results of Ry... | • Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg dosing of ARM210 d... |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vi... | • First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunct... |
| 23.01.2024 | Azafaros to present data from PRONTO study in patients with ... | • Four posters with baseline data from the natural history (PRONTO) study in patients with GM1 and G... |
| 23.01.2024 | Forbion announces 75 million EUR Series A financing in Callu... | • Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics to develop n... |
| 22.01.2024 | Investing in vision: Innovation in retinal therapeutics and ... | Publication: Progress in Retinal and Eye Research |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent ... |
| 11.01.2024 | Dyne Therapeutics Announces Closing of Public Offering of Co... | WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-s... |
| 09.01.2024 | Forbion portfolio company Aiolos Bio, Inc. (Aiolos) to be ac... | Forbion portfolio company Aiolos Bio, Inc. (Aiolos) is to be acquired by GSK for up to $1.4 billion,... |
| 08.01.2024 | CatalYm Appoints Drug Development Leader Roy Baynes to its B... | - Dr. Roy Baynes, a key architect for the Keytruda® program, joins Catalym’s Board of Directors to p... |
| 04.01.2024 | Dyne Therapeutics Announces Pricing of $300 Million Public O... | WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-s... |
| 04.01.2024 | Kynexis Announces Initiation of First-in-Human Phase 1 Study... | Naarden, The Netherlands – January 4, 2024 – Kynexis, a biotechnology company focused on precision t... |
| 14.12.2023 | Complement Therapeutics Announces the Establishment of Medic... | Munich, Germany – 14th December 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biote... |
| 12.12.2023 | Aiolos Bio Strengthens and Expands Leadership Team with Key ... | • René van der Merwe, MBChB, appointed as Chief Medical Officer • Tapan Maniar, Ph.D., joins as Chie... |
| 11.12.2023 | Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in... | • Topline data from the study, expected for mid-2024, will support two pivotal Phase 3 trials in GM1... |
| 06.12.2023 | CatalYm Presents Positive Phase 2a Outcome for Visugromab in... | - Visugromab demonstrated potent and durable clinical efficacy as well as excellent tolerability in ... |
| 13.11.2023 | Forbion co-leads €129 million Series A financing of VectorY,... | • Round co-led by Forbion and EQT Life Sciences • Financing will support clinical development of VTx... |
| 09.11.2023 | Complement Therapeutics Enrols First US Participant in the N... | Munich, Germany – 09 November 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotech... |
| 08.11.2023 | AAVantgarde Appoints Dr. Peter K. Kaiser to the Board of Dir... | November 8, 2023 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biot... |
| 07.11.2023 | Forbion Leads €57 Million Series A Financing in Kynexis, a N... | Naarden, The Netherlands , November 7, 2023 - Forbion, a leading European life sciences venture capi... |
| 01.11.2023 | enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Me... | - Business combination transaction completed with Forbion European Acquisition Corp. - Clinical stag... |
| 30.10.2023 | AAVantgarde Appoints Michael Heffernan as Chairman of its Bo... | - Brings over 30 years of experience building private and public development-stage biopharmaceutical... |
| 24.10.2023 | Forbion leads $85M Series A Financing in Rampart Bioscience | Naarden, The Netherlands, October 24, 2023 – Forbion, a leading European life sciences venture capit... |
| 24.10.2023 | Forbion co-leads $245 million Series A financing of Aiolos | • Series A financing round co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinno... |
| 24.10.2023 | Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial ... | Initial safety, efficacy and durability data expected in 2H’24 |
| 20.10.2023 | The ESMO Conference | Forbion Analyst Melanie de Almeida, PhD will be at the ESMO Congress taking place in Madrid, Spain, ... |
| 17.10.2023 | NorthSea Therapeutics Receives FDA Rare Pediatric Disease De... | Amsterdam, The Netherlands, October 17 — NorthSea Therapeutics B.V. (NST), a biotech company develop... |
| 17.10.2023 | Forbion Impact Report 2022 | In our investments, we focus on addressing high and unmet medical needs and improving the quality of... |
| 17.10.2023 | Forbion Portfolio company Tessellate BIO emerges from stealt... | • The company aims to become a global leader in precision oncology by redefining Synthetic Lethality... |
| 16.10.2023 | Forbion Policy for Responsible Investments 2023 | - |
| 11.10.2023 | AM-Pharma Announces Positive Clinical Data From Phase 1b Stu... | • Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers and a... |
| 02.10.2023 | Fierce Biotech - ‘The fundamentals are really strong’: Why i... | Fierce Biotech's James Waldron covered the biotech industry with a review to date. He explains that ... |
| 26.09.2023 | EUVC #223 - Podcast with Forbion Partner Juliette Audet | With €3 bn under management, Forbion is considered to be one of Europe's leading BioTech firms. List... |
| 21.09.2023 | NewAmsterdam Pharma Announces Initial Data from Phase 2a Cli... | • Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”)... |
| 15.09.2023 | Pharma deal making: a bright spot amid the gloom | Nature Biotech's Melanie Senior delved into expections for the 2023 biotech outlook in her piece &qu... |
| 12.09.2023 | AAVantgarde Appoints Dr. Doug Kerr to the Board of Directors | September 12, 2023 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international bi... |
| 17.08.2023 | AMG Completes Investment in Forbion | WEST PALM BEACH, Fla., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Affiliated Managers Group, Inc. (NYSE: AMG)... |
| 14.08.2023 | IPLS Amsterdam Future Life Cycles | Forbion General Partner Wouter Joustra will be a guest speaker at the 17th Annual IPSL Amsterdam Fut... |
| 14.08.2023 | NewAmsterdam Pharma Announces Appointment of William “BJ” Jo... | Naarden, the Netherlands and Miami, USA; August 14, 2023 – NewAmsterdam Pharma Company N.V. (Nasdaq:... |
| 10.08.2023 | Forbion Portfolio Company Inversago Pharma to be acquired by... | • Acquisition by Novo Nordisk for up to USD 1.075 billion in cash pending milestones • Inversago Pha... |
| 25.07.2023 | NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 ... | -- Expect to Randomize greater than 2500 Patients, Exceeding the 2400 Patient Target -- Topline Resu... |
| 25.07.2023 | Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni,... | • Newly appointed CEO has over 20 years’ experience in company building and strategic business devel... |
| 20.07.2023 | Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitme... | General Partner Rogier Rooswinkel was a contributing author to the article "Tumor-derived GDF-1... |
| 19.07.2023 | ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM21... | • Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Poly... |
| 14.07.2023 | Lilly to Acquire Versanis to Improve Patient Outcomes in Car... | INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versa... |
| 12.07.2023 | Sifted - The 10 most active techbio investors in Europe | Forbion was included in Sifted's list of "The 10 most active techbio investors in Europe".... |
| 05.07.2023 | Pheon Therapeutics enters into license agreement with Biocyt... | Exclusive license agreement for an oncological target antibody to develop best-in-class ADC |
| 27.06.2023 | AMG Announces Partnership with Forbion | • AMG to invest in Forbion, a leading pan-European life sciences venture capital and growth equity f... |
| 27.06.2023 | Allecra Therapeutics Submits New Drug Application to the U.S... | SAINT-LOUIS, France and WEIL AM RHEIN, Germany, June 27, 2023 - Allecra Therapeutics (“Allecra”) ann... |
| 23.06.2023 | Inversago Pharma Presents Data from Phase 1b Trial of INV-20... | -Study results demonstrated favorable safety, tolerability, and PK profile -Clinically significant w... |
| 21.06.2023 | Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executi... | Company is well-positioned to advance robust clinical-stage CNS pipeline, following oversubscribed S... |
| 21.06.2023 | OMEICOS Therapeutics Receives 2.5 million Euros in Grant Fun... | BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company developing first-in-class smal... |
| 13.06.2023 | Inv€$tival Showcase | The Inv€$tival Showcase offers up 7 incredible stages for startup, growth stage and publicly listed ... |
| 13.06.2023 | Jefferies 2023 London Healthcare Conference | The Jefferies 2023 London Healthcare Conference takes place from 14 - 16 November 2023. |
| 13.06.2023 | International Partnering, Strategy & Investment for Nord... | The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conferen... |
| 13.06.2023 | BioEurope Fall | BIO-Europe convenes over 5,000 attendees, representing 60 countries and 2,220+ companies, making the... |
| 13.06.2023 | Nordic Life Science Days | Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science i... |
| 13.06.2023 | Complement Therapeutics Unveils State-of-the-Art Laboratory ... | Munich, Germany – 13th June 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechno... |
| 12.06.2023 | On the Road Amsterdam 2023 | For three decades BioCentury has helped biotech executives and investors make business critical deci... |
| 08.06.2023 | Azafaros Announces Enrollment of First Patient in Phase 2 RA... | • RAINBOW study design enables rapid advancement into the company’s planned Phase 3 efficacy trial... |
| 07.06.2023 | BioInvent announces additional efficacy data from intravenou... | One additional patient has developed a partial response (PR) and one patient has remained on stable ... |
| 06.06.2023 | NewAmsterdam Pharma Announces Pricing of Upsized Secondary O... | NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.... |
| 06.06.2023 | Forbion co-leads €61 Million Series A Financing in AAVantgar... | Naarden, The Netherlands and Munich, Germany, June 06, 2023 — Forbion, a leading European life scien... |
| 05.06.2023 | NewAmsterdam Pharma Announces Positive Topline Results from ... | -- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < ... |
| 05.06.2023 | Replimune Appoints Veleka R. Peeples-Dyer to its Board of Di... | WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical st... |
| 22.05.2023 | Ironwood Enters into Definitive Agreement to Acquire VectivB... | - Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company - - Adds apra... |
| 17.05.2023 | enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”,... | • Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC... |
| 15.05.2023 | Forbion co-leads €40 million Series A in Dualyx | Naarden, The Netherlands and Munich, Germany, 15 May, 2023 – Forbion, a leading European life scienc... |
| 04.05.2023 | Forbion appoints Silva Deželan, PhD as Head of Impact and ES... | Naarden, The Netherlands and Munich, Germany – 4 May 2023 – Forbion, a leading European life science... |
| 24.04.2023 | NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 ... | NAARDEN, the Netherlands and MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N... |
| 19.04.2023 | Forbion raises €1.35 billion across two funds | • Forbion’s largest fundraising to date • €750 million raised in the final close of the Forbion Vent... |
| 17.04.2023 | Forbion co-leads €72 Million Series A Financing in Complemen... | Naarden, The Netherlands – 17 April 2023 - Forbion, a leading European life sciences venture capital... |
| 09.04.2023 | Anglo Nordic Life Science Conference | Anglonordic has a 20-year tradition as an invitation-only gathering of investors and R&D growth ... |
| 09.04.2023 | Bio€quity Europe 2023 | For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partne... |
| 09.04.2023 | BioVaria Munich | Forbion Partner Dmitrij Hristodorov, PhD will be a judge at the 2023 BioVaria which takes place in M... |
| 09.04.2023 | Swiss Biotech Day | The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed ... |
| 09.04.2023 | 23rd Annual Biotech in Europe Forum | The 23rd Annual Biotech in Europe Forum will take place on the 20th - 21st of September 2023 at the ... |
Show more
Mentions in press and media 101
| Date | Title | Description | Source |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeuti... | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pi... | forbion.co... |
| 22.03.2024 | Capstan Therapeutics Secures $175M in Series B Financing wit... | Capstan Therapeutics, a biotechnology company on the cutting edge of in vivo cell reprogramming, has... | parsers.vc... |
| 20.03.2024 | Forbion Invests in Capstan Therapeutics with participation i... | • Nanna Luneborg, PhD, MBA, General Partner at Forbion to join Capstan Board of Directors • Capstan ... | forbion.co... |
| 19.03.2024 | Engrail Therapeutics raises $157M Series B | Engrail Therapeutics, a precision neuroscience company focused on the development of transformationa... | eightroads... |
| 19.03.2024 | Forbion co-leads oversubscribed $157M Series B Financing Rou... | • Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental ... | forbion.co... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application... | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pr... | svhealthin... |
| 29.02.2024 | Forbion co-leads €26 million Seed Financing with launch of O... | • The financing, led by Forbion and Novo Holdings, will support Orbis’ expansion and advancement of ... | forbion.co... |
| 23.01.2024 | Forbion announces 75 million EUR Series A financing in Callu... | • Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics to develop n... | forbion.co... |
| 13.11.2023 | Forbion co-leads €129 million Series A financing of VectorY,... | • Round co-led by Forbion and EQT Life Sciences • Financing will support clinical development of VTx... | forbion.co... |
| 13.11.2023 | Forbion co-leads €129 million Series A financing of VectorY,... | - | globenewsw... |
| 07.11.2023 | Forbion Leads €57 Million Series A Financing in Kynexis, a N... | Naarden, The Netherlands , November 7, 2023 - Forbion, a leading European life sciences venture capi... | forbion.co... |
| 24.10.2023 | Forbion co-leads $245 million Series A financing of Aiolos | • Series A financing round co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinno... | forbion.co... |
| 24.10.2023 | Forbion leads $85M Series A Financing in Rampart Bioscience | Naarden, The Netherlands, October 24, 2023 – Forbion, a leading European life sciences venture capit... | forbion.co... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are stay... | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused ventur... | fiercebiot... |
| 06.06.2023 | Forbion co-leads €61 Million Series A Financing in AAVantgar... | Naarden, The Netherlands and Munich, Germany, June 06, 2023 — Forbion, a leading European life scien... | forbion.co... |
| 15.05.2023 | Forbion co-leads €40 million Series A in Dualyx | Naarden, The Netherlands and Munich, Germany, 15 May, 2023 – Forbion, a leading European life scienc... | forbion.co... |
| 11.05.2023 | Il mercato del Venture Capital ad aprile 2023 | Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle s... | startup-ne... |
| 20.04.2023 | Forbion Raises €1.35 Billion Across Two Funds | Forbion, a Naarden, The Netherlands and Munich, Germany-based life sciences venture capital firm, ra... | finsmes.co... |
| 19.04.2023 | Forbion raises €1.35 billion across two funds | • Forbion’s largest fundraising to date • €750 million raised in the final close of the Forbion Vent... | forbion.co... |
| 19.04.2023 | Forbion points to high investor demand in €1.3B raise for la... | If you needed further reassurance that VC investor sentiment in biotech is starting to rebound, look... | fiercebiot... |
| 17.04.2023 | Forbion co-leads €72 Million Series A Financing in Complemen... | Naarden, The Netherlands – 17 April 2023 - Forbion, a leading European life sciences venture capital... | forbion.co... |
| 07.03.2023 | Forbion co-leads CHF 103 million investment in Noema Pharma | Naarden, The Netherlands – 07 March 2023 – Forbion, a leading European life sciences venture capital... | forbion.co... |
| 07.03.2023 | Noema Pharma raises CHF103 million | startuptic... | |
| 28.09.2022 | Forbion Co-leads $68m Investment in Newly Launched Antibody-... | Naarden, The Netherlands – 28 September 2022 – Forbion, a leading European life sciences venture cap... | forbion.co... |
| 04.08.2022 | Forbion Co-leads $70 Million Financing of F2G to Advance Dev... | Naarden, The Netherlands, 4 August 2022 – Forbion, a leading European life sciences venture capital ... | forbion.co... |
| 20.06.2022 | Forbion Holds First Close of Forbion Growth Opportunities Fu... | Forbion, a Naarden, The Netherlands, Munich, Germany-based life sciences venture capital firm, held ... | finsmes.co... |
| 15.06.2022 | Forbion Growth Opportunities Fund II leads USD 50 million pl... | Amsterdam, The Netherlands, 15 June 2022 -- Forbion, a leading European life sciences venture capita... | forbion.co... |
| 09.06.2022 | Forbion announces first close of Forbion Growth Opportunitie... | Naarden, The Netherlands and Munich, Germany – 09 June, 2022 – Forbion, a leading European life scie... | forbion.co... |
| 17.03.2022 | Precirix raises EUR 80m in Series B to advance its pipeline ... | Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing pr... | healthcap.... |
| 16.03.2022 | Forbion co-leads EUR 80m Series B investment in Precirix to ... | Naarden, The Netherlands - 16 March 2022 – Forbion, a leading European life sciences venture capital... | forbion.co... |
| 23.02.2022 | Forbion and BGV announce EUR 5 million seed investment in Co... | Naarden, The Netherlands - 23 February 2022 - Forbion and BioGeneration Ventures (BGV), two leading ... | forbion.co... |
| 20.12.2021 | Forbion leads $35M Series B for ARMGO Pharma | Amsterdam, The Netherlands – 20th December 2021 – Forbion, a leading European life sciences venture ... | forbion.co... |
| 16.12.2021 | Anaveon raises CHF 110 million | startuptic... | |
| 16.12.2021 | Forbion to lead oversubscribed CHF 110M Series B for Swiss i... | Amsterdam, The Netherlands – 16 December 2021 – Forbion, a leading European life sciences venture ca... | forbion.co... |
| 10.12.2021 | Forbion European Acquisition Corp. Announces Pricing of $110... | NAARDEN, Netherlands, Dec. 9, 2021 /PRNewswire/ -- Forbion European Acquisition Corp. (the "Com... | marketscre... |
| 09.12.2021 | Forbion European Acquisition Corp. Announces Pricing of $110... | NAARDEN, THE NETHERLANDS, December 9, 2021 (PRNewswire) — Forbion European Acquisition Corp. (the “C... | forbion.co... |
| 14.10.2021 | Forbion Co-Leads New Investment in Rectify Pharmaceuticals W... | Naarden, The Netherlands, 14 October 2021 – Forbion, a leading European life sciences venture capita... | forbion.co... |
| 03.08.2021 | Mestag Therapeutics Extends Seed Financing to $45 Million an... | - Oversubscribed seed round supports the development of impactful medicines targeting activated fibr... | svhealthin... |
| 03.08.2021 | Forbion Leads €28.6million Seed Extension Financing for Mest... | Naarden, The Netherlands, 3 August 2021 – Forbion, a leading European life sciences venture capital ... | forbion.co... |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 finan... | NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (N... | fh-partner... |
| 02.07.2021 | CureVac gains COO and hands Florian von der Mülbe new as... | Malte Greune → Aiming to bounce back and trying to accentuate the positive after its mRNA ... | endpts.com... |
| 15.06.2021 | Forbion co-leads VectorY EUR 31 million seed financing | Amsterdam, The Netherlands – 15 June 2021 – Forbion, a leading European life sciences venture capita... | forbion.co... |
| 20.05.2021 | Forbion’s Growth Opportunities Fund completes EUR 91 million... | Amsterdam, The Netherlands, 20 May 2021 – Forbion, a leading European life sciences venture capital ... | forbion.co... |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financ... | startuptic... | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financ... | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific... | startuptic... |
| 20.04.2021 | Forbion closes final European life sciences funding round at... | Using the tailwinds of the pandemic, Forbion has raised a healthy €360 million ($428 million) to inv... | fiercebiot... |
| 20.04.2021 | Forbion : Announces Final Close of Forbion : Growth Opportun... | Forbion, a leading European life sciences venture capital firm, today announces the final close of i... | marketscre... |
| 20.04.2021 | Forbion announces final close of Forbion Growth Opportunitie... | Naarden, The Netherlands and Munich, Germany – 20 April 2021 – Forbion, a leading European life scie... | forbion.co... |
| 26.03.2021 | Forbion’s Growth Opportunities Fund leads $148M Series C Fin... | Amsterdam, The Netherlands, 26 March 2021 – Forbion, a leading European life sciences venture capita... | forbion.co... |
| 09.12.2020 | Forbion Closes Fifth Life Sciences Fund, at €460M | Forbion, a Naarden, The Netherlands and Munich, Germany-based life science venture capital firm, sec... | finsmes.co... |
| 08.12.2020 | Forbion raises €460M in weeks to back next crop of EU biotec... | Forbion has raised a €460 million ($558 million) early-stage venture capital fund. The fund hit its ... | fiercebiot... |
| 08.12.2020 | Forbion : secures EUR 460 million for oversubscribed fifth f... | Forbion, a leading European life science venture capital firm, today announces having secured its fi... | marketscre... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmace... | incubees.c... |
| 18.11.2020 | Axon refuerza su liderazgo en el sector de Life Sciences con... | 18/11/2020 Nota de prensa AXON REFUERZA SU LIDERAZGO EN EL SECTOR DE LIFE SCIENCES CON 2 NUEVAS IN... | webcapital... |
| 08.09.2020 | adMare is pleased to increase our investment in Inversago Ph... | Inversago Pharma closes US$35M Series B financing round and expands Board of Directors Vancouver and... | admarebio.... |
| 09.07.2020 | Forbion moves into late-stage investing with $210M fund | Forbion has expanded into late-stage biotech investing by holding the first close of a planned €250 ... | fiercebiot... |
| 09.07.2020 | Forbion Holds First Close of Growth Opportunities Fund, at €... | Forbion, a Naarden, The Netherlands-, Munich, Germany- and Singapore-based life sciences venture cap... | finsmes.co... |
| 09.07.2020 | Forbion moves into late-stage investing with $210M fund | Forbion has expanded into late-stage biotech investing by holding the first close of a planned €250 ... | fiercebiot... |
| 03.12.2018 | Forbion Adds Carlo Incerti as Operating Partner | Forbion, a European life science venture capital firm, will add Carlo Incerti, M.D., as Operating Pa... | finsmes.co... |
| 01.10.2018 | Forbion closes fourth EU-focused biotech fund at €360M | Forbion has closed its fourth fund at €360 million ($417 million). The addition of €90 million since... | fiercebiot... |
| 01.10.2018 | Forbion Closes Fourth Life Sciences VC Fund, at €360M | Forbion, a Naarden, The Netherlands- and Munich, Germany-based life science venture capital firm, he... | finsmes.co... |
| 01.10.2018 | Forbion closes fourth EU-focused biotech fund at €360M W h ... | Forbion has closed its fourth fund at €360 million ($417 million). The addition of €90 million since... | fiercebiot... |
| 12.07.2018 | Term Sheet – Thursday, July 12 | MIX TAPE Good morning all! Lucinda back again for today and Friday. Reach me lucinda.shen@fortune.co... | fortune.co... |
| 11.07.2018 | Forbion raises €270M, EU-focused life science fund | Forbion has raised a €270 million ($316 million), Europe-focused life sciences fund. The bumper firs... | fiercebiot... |
| 11.07.2018 | Forbion Holds €270M First Close of Fourth Life Sciences VC F... | Forbion, a Naarden, The Netherlands, and Munich, Germany-based life science venture capital firm, he... | finsmes.co... |
| 07.02.2017 | Prexton Therapeutics, participada por Ysios, cierra una rond... | 07/02/2017 Nota de prensa PREXTON THERAPEUTICS, PARTICIPADA POR YSIOS CAPITAL, CIERRA UNA RONDA DE... | webcapital... |
| 07.02.2017 | Prexton Therapeutics €29M in Series B Financing | Prexton Therapeutics, a Geneva, Switzerland and Amsterdam, The Netherlands-based biopharmaceutical c... | finsmes.co... |
| 07.02.2017 | Prexton Therapeutics raises CHF31 million | startuptic... | |
| 12.04.2016 | Forbion Capital Partners Closes Third Life Sciences Fund, at... | Forbion Capital Partners, a Naarden, The Netherlands, and Munich, Germany-based life sciences ventur... | finsmes.co... |
| 16.02.2016 | Akarna Therapeutics Closes $15M Series B Financing | Akarna Therapeutics Ltd., a Cambridge, UK- and Encinitas, California-based biopharmaceutical company... | finsmes.co... |
| 24.09.2015 | Daily funding roundup - September 24, 2015 | Premise bagged $50M; Replimune closed $30M Series A financing; DriverUp raised $20M Crowdway, a Mila... | vator.tv/n... |
| 10.09.2015 | Forbion Capital Partners Closes Co-Investment Fund I at €75M... | Life Sciences venture capital firm Forbion Capital Partners has closed its its Forbion Capital Fund ... | finsmes.co... |
| 08.09.2015 | Sanifit cierra una ronda de €36,6M liderada por Ysios. Acude... | 08/09/2015 SANIFIT CIERRA UNA RONDA DE €36,6 MILLONES LIDERADA POR YSIOS. ACUDEN CAIXA CAPITAL RISC... | webcapital... |
| 22.05.2015 | Fonds de solidarité FTQ Invests €10.5M in Netherlands-based ... | In an effort to attract international life science funds to Québec, the Fonds de solidarité FTQ is i... | finsmes.co... |
| 24.03.2015 | Rigontec Raises €4.8M in Second Closing of Series A Financin... | Rigontec GmbH, a Bonn, Germany-based biopharmaceutical company developing RNA-based immunotherapeuti... | finsmes.co... |
| 06.10.2014 | Biotech backer Forbion raises $120M toward a new VC fund | The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, ra... | fiercebiot... |
| 29.09.2014 | Pulmologix Raises €9.6M | Pulmologix, a Stockholm, Sweden-based developer of a new oral non-steroidal anti-asthmatic drug, rai... | finsmes.co... |
| 04.11.2013 | Hookipa Biotech Raises €20M in Series B Equity Financing | Hookipa Biotech AG, a Vienna, Austria-based developer of a new class of vaccines, raised €20m ($27.5... | finsmes.co... |
| 13.08.2013 | New non-invasive test for prostate cancer may identify sever... | Exosome Diagnostics, Inc. has recently conducted a multi-center clinical study program for EXO106, t... | medcitynew... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenole... | medcitynew... |
| 08.03.2012 | Fibrotic disease company raises $21 million in series D roun... | The financing was led by Fibrotic Ventures. It also received additional funding from existing ventur... | medcitynew... |
| 30.11.2011 | CircuLite Raises $30M in Series D Funding | CircuLite, Inc., a Saddle Brook, NJ-based developer of innovative solutions to improve the treatment... | finsmes.co... |
| 30.11.2011 | Blood pump implant developer completes $30 million series D ... | The funding will also go toward U.S. clinical development of its Synergy pump system from a pilot in... | medcitynew... |
| 17.11.2011 | Oxyrane Raises $26.5M in Series D Funding | Oxyrane UK Limited, a Manchester, England, UK-based biopharmaceutical company dedicated to the devel... | finsmes.co... |
| 26.10.2011 | Hookipa Biotech Raises €7M in Series A Financing | Hookipa Biotech, an Austrian biotech startup specialized in developing new generation vaccines, has ... | finsmes.co... |
| 26.10.2011 | Curetis Raises €9.6M in Series A Financing | Curetis AG, a Holzgerlingen near Stuttgart, Germany-based molecular diagnostics company which focuse... | finsmes.co... |
| 06.09.2011 | gIcare Pharma Closes CAD$7M Series A Financing | gIcare Pharma, Inc., a Montreal, Canada-based pharmaceutical developer of proprietary therapeutic dr... | finsmes.co... |
| 06.09.2011 | Amakem NV Raises €18M in Series A Financing Round | Amakem NV, a Hasselt, Belgium-based ophthalmology company developing new treatments for serious eye ... | finsmes.co... |
| 04.01.2011 | PneumRx Raises $33M | PneumRx, Inc., a Mountain View, California-based medical device company focused on the development a... | finsmes.co... |
| 03.09.2010 | Forbion Capital Partners Closes Two Funds Raising €190M | Forbion Capital Partners, a Naarden, Netherlands-based venture capital firm focused on investing in ... | finsmes.co... |
| 19.07.2010 | Mitralign wins $5 million credit line from GE Capital | GE Capital’s Healthcare Financial Services division gave Mitralign Inc. a $5 million line of credit.... | massdevice... |
| 30.03.2009 | Pathway Medical lands generous $40M to treat arterial diseas... | Pathway Medical Technologies, maker of a non-invasive catheter capable of removing all kinds of arte... | venturebea... |
| 09.07.2007 | BioVex raises $22M for cancer-killing viruses | Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $2... | venturebea... |
| - | New non-invasive test for prostate cancer may identify sever... | Exosome Diagnostic, Inc., has developed a revolutionary non-invasive approach to molecular diagnosti... | medcitynew... |
| - | Blood pump implant developer completes $30 million series D ... | CircuLite, a Saddle Brook, New Jersey medical device company, has raised $30 million in an oversubsc... | medcitynew... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Company name: bluebird bio. Industry: Biotechnology. Location: Cambridge, Massachusetts. Product: Ge... | medcitynew... |
| - | RSPR Pharma hires Paul de Potocki as Chief Business Officer | Stockholm 2016-08-23 RSPR Pharma AB today announced that Paul de Potocki will join the company as C... | healthcap.... |
| - | Fibrotic disease company raises $21 million in series D roun... | A biotechnology company developing therapeutics for fibrotic diseases has raised $21.5 million in a ... | medcitynew... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceut... | healthcap.... |
| - | Pulmologix raises € 9.6 million to develop a new oral non-st... | Press release Stockholm 2014-09-16 Pulmologix AB today announced the closing of a series B financin... | healthcap.... |
Show more